Success Metrics

Clinical Success Rate

57.1%

Based on 4 completed trials

Completion Rate

57%(4/7)

Active Trials

3(20%)

Results Posted

75%(3 trials)

Terminated

3(20%)

Phase Distribution

Ph phase_3

Ph phase_1

40%

Ph phase_2

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution13 total trials

Phase 1Safety & dosage

6(46.2%)

Phase 2Efficacy & side effects

6(46.2%)

Phase 3Large-scale testing

1(7.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

4 of 10 finished

Non-Completion Rate

60.0%

6 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(4)

Terminated(6)

Other(2)

Detailed Status

Completed4

Withdrawn3

Terminated3

Recruiting3

unknown2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

57.1%

Most Advanced

Phase 3

Trials by Phase

Phase 16 (46.2%)

Phase 26 (46.2%)

Phase 31 (7.7%)

Trials by Status

completed427%

withdrawn320%

terminated320%

unknown213%

recruiting320%

Recent Activity

3 active trials

Showing 5 of 15

recruitingphase_3

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

NCT03932643

recruitingphase_2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

NCT05009992

View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials

NCT05476939Phase 3

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Recruiting

NCT05542407Phase 1

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Recruiting

NCT06012929Phase 2

A Study of ONC201 for Refractory Meningioma

Withdrawn

NCT03932643Phase 1

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Completed

NCT05009992Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recruiting

NCT03099499Phase 2

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Terminated

NCT03034200Phase 2

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Completed

NCT02863991Phase 1

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Terminated

NCT04629209Phase 2

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Withdrawn

NCT03394027Phase 2

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Completed

NCT05392374

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Unknown

NCT03134131

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Unknown

NCT02609230Phase 1

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Completed

NCT02038699Phase 1

A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer

Withdrawn

NCT03492138Phase 1

Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Terminated

All 15 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 15